Deep Learning Derived Histopathology Image Score for Increasing Phase 3 Clinical Trial Probability of Success

• URL: http://arxiv.org/abs/2011.05406v1
• Date: Tue, 10 Nov 2020 21:26:13 GMT
• Title: Deep Learning Derived Histopathology Image Score for Increasing Phase 3 Clinical Trial Probability of Success
• Authors: Qi Tang and Vardaan Kishore Kumar
• Abstract summary: Failures in Phase 3 clinical trials contribute to expensive cost of drug development in oncology. We pioneered the use of deep-learning derived digital pathology scores to identify responders.
• Score: 0.462316736194615
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Failures in Phase 3 clinical trials contribute to expensive cost of drug development in oncology. To drastically reduce such cost, responders to an oncology treatment need to be identified early on in the drug development process with limited amount of patient data before the planning of Phase 3 clinical trials. Despite the challenge of small sample size, we pioneered the use of deep-learning derived digital pathology scores to identify responders based on the immunohistochemistry images of the target antigen expressed in tumor biopsy samples from a Phase 1 Non-small Cell Lung Cancer clinical trial. Based on repeated 10-fold cross validations, the deep-learning derived score on average achieved 4% higher AUC of ROC curve and 6% higher AUC of Precision-Recall curve comparing to the tumor proportion score (TPS) based clinical benchmark. In a small independent testing set of patients, we also demonstrated that the deep-learning derived score achieved numerically at least 25% higher responder rate in the enriched population than the TPS clinical benchmark.

Related papers

• ICU-TSB: A Benchmark for Temporal Patient Representation Learning for Unsupervised Stratification into Patient Cohorts [0.055923945039144905]
  We introduce ICU-TSB (Temporal Stratification Benchmark), the first benchmark for evaluating patient stratification based on temporal patient representation learning.<n>A key contribution of our benchmark is a novel hierarchical evaluation framework utilizing disease to measure the alignment of discovered clusters with clinically validated disease groupings.<n>Our results demonstrate that temporal representation learning can rediscover clinically meaningful patient cohorts.
  arXiv  Detail & Related papers  (2025-06-06T15:52:50Z)
• Quantifying the Reasoning Abilities of LLMs on Real-world Clinical Cases [48.87360916431396]
  We introduce MedR-Bench, a benchmarking dataset of 1,453 structured patient cases, annotated with reasoning references. We propose a framework encompassing three critical examination recommendation, diagnostic decision-making, and treatment planning, simulating the entire patient care journey. Using this benchmark, we evaluate five state-of-the-art reasoning LLMs, including DeepSeek-R1, OpenAI-o3-mini, and Gemini-2.0-Flash Thinking, etc.
  arXiv  Detail & Related papers  (2025-03-06T18:35:39Z)
• Arges: Spatio-Temporal Transformer for Ulcerative Colitis Severity Assessment in Endoscopy Videos [2.0735422289416605]
  Expert MES/UCEIS annotation is time-consuming and susceptible to inter-rater variability. CNN-based weakly-supervised models with end-to-end (e2e) training lack generalization to new disease scores. "Arges" is a deep learning framework that incorporates positional encoding to estimate disease severity scores in endoscopy.
  arXiv  Detail & Related papers  (2024-10-01T09:23:14Z)
• Language Interaction Network for Clinical Trial Approval Estimation [37.60098683485169]
  We introduce the Language Interaction Network (LINT), a novel approach that predicts trial outcomes using only the free-text descriptions of the trials. We have rigorously tested LINT across three phases of clinical trials, where it achieved ROC-AUC scores of 0.770, 0.740, and 0.748.
  arXiv  Detail & Related papers  (2024-04-26T14:50:59Z)
• TrialDura: Hierarchical Attention Transformer for Interpretable Clinical Trial Duration Prediction [19.084936647082632]
  We propose TrialDura, a machine learning-based method that estimates the duration of clinical trials using multimodal data. We encode them into Bio-BERT embeddings specifically tuned for biomedical contexts to provide a deeper and more relevant semantic understanding. Our proposed model demonstrated superior performance with a mean absolute error (MAE) of 1.04 years and a root mean square error (RMSE) of 1.39 years compared to the other models.
  arXiv  Detail & Related papers  (2024-04-20T02:12:59Z)
• Multimodal Deep Learning for Personalized Renal Cell Carcinoma Prognosis: Integrating CT Imaging and Clinical Data [3.790959613880792]
  Renal cell carcinoma represents a significant global health challenge with a low survival rate. This research aimed to devise a comprehensive deep-learning model capable of predicting survival probabilities in patients with renal cell carcinoma. The proposed framework comprises three modules: a 3D image feature extractor, clinical variable selection, and survival prediction.
  arXiv  Detail & Related papers  (2023-07-07T13:09:07Z)
• AutoTrial: Prompting Language Models for Clinical Trial Design [53.630479619856516]
  We present a method named AutoTrial to aid the design of clinical eligibility criteria using language models. Experiments on over 70K clinical trials verify that AutoTrial generates high-quality criteria texts.
  arXiv  Detail & Related papers  (2023-05-19T01:04:16Z)
• SPOT: Sequential Predictive Modeling of Clinical Trial Outcome with Meta-Learning [67.8195828626489]
  Clinical trials are essential to drug development but time-consuming, costly, and prone to failure. We propose Sequential Predictive mOdeling of clinical Trial outcome (SPOT) that first identifies trial topics to cluster the multi-sourced trial data into relevant trial topics. With the consideration of each trial sequence as a task, it uses a meta-learning strategy to achieve a point where the model can rapidly adapt to new tasks with minimal updates.
  arXiv  Detail & Related papers  (2023-04-07T23:04:27Z)
• Exploiting segmentation labels and representation learning to forecast therapy response of PDAC patients [60.78505216352878]
  We propose a hybrid deep neural network pipeline to predict tumour response to initial chemotherapy. We leverage a combination of representation transfer from segmentation to classification, as well as localisation and representation learning. Our approach yields a remarkably data-efficient method able to predict treatment response with a ROC-AUC of 63.7% using only 477 datasets in total.
  arXiv  Detail & Related papers  (2022-11-08T11:50:31Z)
• A Generic Deep Learning Based Cough Analysis System from Clinically Validated Samples for Point-of-Need Covid-19 Test and Severity Levels [85.41238731489939]
  We seek to evaluate the detection performance of a rapid primary screening tool of Covid-19 based on the cough sound from 8,380 clinically validated samples. Our proposed generic method is an algorithm based on Empirical Mode Decomposition (EMD) with subsequent classification based on a tensor of audio features. Two different versions of DeepCough based on the number of tensor dimensions, i.e. DeepCough2D and DeepCough3D, have been investigated.
  arXiv  Detail & Related papers  (2021-11-10T19:39:26Z)
• Controlling False Positive/Negative Rates for Deep-Learning-Based Prostate Cancer Detection on Multiparametric MR images [58.85481248101611]
  We propose a novel PCa detection network that incorporates a lesion-level cost-sensitive loss and an additional slice-level loss based on a lesion-to-slice mapping function. Our experiments based on 290 clinical patients concludes that 1) The lesion-level FNR was effectively reduced from 0.19 to 0.10 and the lesion-level FPR was reduced from 1.03 to 0.66 by changing the lesion-level cost.
  arXiv  Detail & Related papers  (2021-06-04T09:51:27Z)
• MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response [58.0291320452122]
  This paper aims at a unified deep learning approach to predict patient prognosis and therapy response. We formalize the prognosis modeling as a multi-modal asynchronous time series classification task. Our predictive model could further stratify low-risk and high-risk patients in terms of long-term survival.
  arXiv  Detail & Related papers  (2020-10-08T15:30:17Z)
• A deep learning-facilitated radiomics solution for the prediction of lung lesion shrinkage in non-small cell lung cancer trials [2.929792935431798]
  We propose a deep learning-based approach for the prediction of lung lesion response based on radiomic features extracted from clinical CT scans of patients in non-small cell lung cancer trials. A 5-fold cross validation on the training set led to an AUC of 0.84 +/- 0.03, and the prediction on the testing dataset reached AUC of 0.73 +/- 0.02 for the outcome of 30% diameter shrinkage.
  arXiv  Detail & Related papers  (2020-03-05T21:49:42Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.